<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02350764</url>
  </required_header>
  <id_info>
    <org_study_id>14-137</org_study_id>
    <nct_id>NCT02350764</nct_id>
  </id_info>
  <brief_title>Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs</brief_title>
  <official_title>An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to closely examine tumor and blood samples from patients treated&#xD;
      with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers&#xD;
      respond and why some patients do not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response rate (confirmed partial + complete response) will be assessed as part of this study. Tumor response will be assessed using RECIST 1.1)</measure>
    <time_frame>every 6 weeks (+/- 1 week) until week 48</time_frame>
    <description>confirmed partial + complete response will be assessed as part of this study. Tumor response will be assessed using RECIST 1.1. All responses must be confirmed on subsequent scan to be considered a true response. Tumor assessments will be performed after.6 weeks (+/- 1 week) and subsequently every six week (+/- 1 week) thereafter while on study until week 48. After week 48, tumor assessments will be conducted every 12 weeks (+/- week). Additional tumor assessments may be performed at the discretion of the treating physician.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Advanced Stage Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease*, withdrawal of consent, or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pilimumab</intervention_name>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be capable, willing, and able to provide written, informed consent.&#xD;
&#xD;
          -  ≥ 18 years old.&#xD;
&#xD;
          -  Advanced stage NSCLC&#xD;
&#xD;
          -  Previously treated with no more than two lines of prior systemic therapy for advanced&#xD;
             stage lung cancer.&#xD;
&#xD;
               -  Patients who previously received neoadjuvant, concurrent, or adjuvant&#xD;
                  chemotherapy for localized NSCLC and then recurred within 6 months of completing&#xD;
                  chemotherapy may be considered as having received one line of prior therapy&#xD;
&#xD;
               -  Maintenance therapy does not count as a separate line of therapy&#xD;
&#xD;
          -  Patients must:&#xD;
&#xD;
               -  Be scheduled to undergo a standard-of-care resection of tumor tissue as part of&#xD;
                  treatment plan prior to beginning study therapy. Patients may not have&#xD;
                  intervening systemic anti-cancer therapy between the time of resection and&#xD;
                  treatment with nivolumab.&#xD;
&#xD;
               -  Have collection of adequate pre-treatment tissue for correlative analysis defined&#xD;
                  as sufficient material for 1) frozen tissue for DNA/RNA with touch&#xD;
                  prep/representative slide confirming tumor material present, 2) FFPE material for&#xD;
                  ICH with touch prep/representative slide confirming tumor material present, and&#xD;
                  3) single-cell suspensions with &gt;20 million live cells after tissue digestion but&#xD;
                  before freezing. Adequacy of collected material will be determined within 5&#xD;
                  business days of each collected case.&#xD;
&#xD;
               -  Have residual disease following surgical resection that is measurable by RECIST&#xD;
                  v1.1&#xD;
&#xD;
               -  Previously irradiated sites of tumor may be considered measurable if there is&#xD;
                  radiographic progression at that site subsequent to the time of completing&#xD;
                  radiation.&#xD;
&#xD;
               -  Have a safely biopsiable tumor lesion&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Adequate hematologic, renal, and/or hepatic function (following criteria must be met&#xD;
             within 28 days of C1D1:&#xD;
&#xD;
               -  WBC ≥ 2,000/ul&#xD;
&#xD;
               -  ANC ≥ 1,500/ul&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dl&#xD;
&#xD;
               -  Platelet count ≥ 100,000/ul&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN (unless evidence of Gilbert's syndrome, in which&#xD;
                  case, direct bilirubin must be ≤ 1.0 x ULN)&#xD;
&#xD;
               -  AST and ALT ≤ 3 x UNL (unless elevated transaminases are felt to be directly&#xD;
                  related to metastatic disease involving the liver, in which case AST and ALT must&#xD;
                  be ≤ 5x ULN)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance of ≥ 40 mL/min&#xD;
                  calculated using the formula of Cockcroft and Gault: (140-Age) • Mass (kg)/(72 •&#xD;
                  creatinine mg/dL); multiply by 0.85 if female&#xD;
&#xD;
          -  There is no restriction on the number of prior lines of systemic anti-cancer therapy.&#xD;
             For those who have received prior systemic anti-cancer therapy, there must be at least&#xD;
             3 weeks since last systemic therapy.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 3 days prior to&#xD;
             the start of study drug.&#xD;
&#xD;
          -  Effective contraception:&#xD;
&#xD;
               -  Women of childbearing potential must agree to practice 2 effective methods of&#xD;
                  contraception from the time of signing the informed consent form through 23 weeks&#xD;
                  (5 half-lifes plus 30 days, the duration of an ovulatory cycle) after the last&#xD;
                  dose of nivolumab, or agree to completely abstain from heterosexual intercourse.&#xD;
&#xD;
               -  Male subjects, even if surgically sterilized (i.e., status post vasectomy) must&#xD;
                  agree to 1 of the following: practice effective barrier contraception during the&#xD;
                  entire study treatment period and through 31 weeks (5 half-lives plus 90 days,&#xD;
                  the duration of sperm turnover) after the last dose of study drug, or completely&#xD;
                  abstain from heterosexual intercourse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant or lactating.&#xD;
&#xD;
          -  Presence of activating EGFR mutations or ALK re-arrangement,unless previously treated&#xD;
             with standard TKI therapy. All patients with adenocarcinoma histology must be tested&#xD;
             for EGFR and ALK status.&#xD;
&#xD;
          -  History of allergy to study drug components or history of severe hypersensitivity&#xD;
             reaction of any monoclonal antibody.&#xD;
&#xD;
          -  Prior treatment with immune checkpoint inhibitor, including (but not limited to) those&#xD;
             targeting PD-1, PD-L1, PD-L2, CTLA-4, CD137, GITR, TIM3, LAG3, or OX40&#xD;
&#xD;
          -  Any systemic anti-cancer therapy within 3 weeks prior to C1D1 of study therapy&#xD;
&#xD;
          -  Exception is made for patients with EGFR or ALK re-arrangements who must have stopped&#xD;
             TKI therapy at least 7 days prior to C1D1&#xD;
&#xD;
          -  Patients who have not previously been treated with platinum-based based doublet&#xD;
             chemotherapy and who, in the judgment of the investigator, have rapidly progressive&#xD;
             disease such that serious complications may arise from disease progression within the&#xD;
             next 12 weeks will be excluded.&#xD;
&#xD;
          -  Non-CNS radiotherapy within 1 week prior to C1D1 of study therapy&#xD;
&#xD;
          -  Active infection requiring therapy&#xD;
&#xD;
          -  Prior systemic immunosuppressive therapy (&gt; 10 mg/day prednisone equivalents) within 1&#xD;
             week prior to C1D1 of study therapy. Inhaled, ocular, intra-articular, intranasal, and&#xD;
             topical corticosteroids are permitted in absence of active autoimmune disease.&#xD;
&#xD;
               -  Adrenal replacement doses are permitted in the absence of active autoimmune&#xD;
                  disease.&#xD;
&#xD;
          -  Patients with known or suspected history of autoimmune disease. Subjects with type I&#xD;
             diabetes melitis, hypothyroidism only requiring hormone replacement, resolved&#xD;
             childhood asthma/atopy, patients with asthma requiring intermittent bronchodilator&#xD;
             therapy, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger are permitted to enroll.&#xD;
&#xD;
          -  Other active malignancy requiring concurrent intervention.&#xD;
&#xD;
          -  Patients with previous malignancies (except non-melanoma skin cancers, and the&#xD;
             following in situ cancers: bladder, gastric, colon, cervical/dysplasia, melanoma, or&#xD;
             breast) are excluded unless definitive therapy has been completed at least 1 year&#xD;
             prior to study entry and the patient is now without evidence of disease from that&#xD;
             malignance and no additional therapy is required or anticipated to be required during&#xD;
             the study period.&#xD;
&#xD;
          -  Known untreated brain or leptomeningeal metastasis.&#xD;
&#xD;
             o Patients with brain metastases are eligible if metastases have been adequately&#xD;
             treated and neurologically returned to baseline (except for residual signs or symptoms&#xD;
             related to the CNS treatment) for at least two weeks prior to C1D1. In addition, must&#xD;
             also be no requirement for immunosuppressive doses of systemic corticosteroids (&gt; 10&#xD;
             mg/day prednisone equivalents) for at least 2 weeks prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Patients with interstitial lung disease that is symptomatic or may interfere with the&#xD;
             detection or management of suspected drug-related pulmonary toxicity.&#xD;
&#xD;
          -  Any positive test for HIV&#xD;
&#xD;
          -  Any positive test for HCV RNA or HBsAg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Schoenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Lung</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>NSCLC</keyword>
  <keyword>14-137</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

